# Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation

Study · id `cardio:ct-nct06364215` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06364215](<https://clinicaltrials.gov/study/NCT06364215>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06364215

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 198 participants.

## Technical summary

Registry record NCT06364215. Randomized; double masking; primary purpose treatment. Start 2024-10-08 (actual); primary completion 2025-11-16 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 198 participants (enrolled count; ClinicalTrials.gov record NCT06364215, source copy `cardio:ctgov-nct06364215-2026-05-15`, retrieved 2026-10-26)
- Started: 2024-10-08 (actual) (ClinicalTrials.gov record NCT06364215, source copy `cardio:ctgov-nct06364215-2026-05-15`, retrieved 2026-10-26)
- Primary completion: 2025-11-16 (actual) (ClinicalTrials.gov record NCT06364215, source copy `cardio:ctgov-nct06364215-2026-05-15`, retrieved 2026-10-26)
- Completion: 2025-11-16 (actual) (ClinicalTrials.gov record NCT06364215, source copy `cardio:ctgov-nct06364215-2026-05-15`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06364215, source copy `cardio:ctgov-nct06364215-2026-05-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06364215-2026-05-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation
- Acronym: (SMILE-AF)
- Condition: Atrial Fibrillation Paroxysmal
- Intervention (Device): Farapulse PFA, Pulmonary Vein Isolation alone
- Intervention (Device): Farapulse PFA, Pulmonary Vein Isolation and Left atrial Posterior Wall Isolation
- Lead sponsor: Jorge Romero
- Lead sponsor class: OTHER
- Collaborator: Boston Scientific Corporation
- Collaborator class: INDUSTRY
- Collaborator: Databean
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as a collaborator: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: 0ed130256505f3d2cb9cc64f3375837ca719eb48ed057efb0e47c5a993e49e9f
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
